Print Friendly, PDF & Email

NCT/Study#

NCT02500407 /

GO29781

An Open-Label, Multicenter, Phase I Trial Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of BTCT4465A In Patients With Relapsed Or Refractory B-Cell Non-Hodgkin?S Lymphoma And Chronic Lymphocytic Leukemia

DISEASE GROUP:
Lymphoma
current phase:
Phase I
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: